Cite
HARVARD Citation
De La Motte Rouge, T. et al. (n.d.). 2755 First real life data on Olaparib in BRCA1/2 mutated Platinum-Sensitive Relapsed (PSR) Epithelial Ovarian Cancer (EOC) in France: Analysis of 52 patients (pts) enrolled in the French Temporary Authorization for Use (ATU). European journal of cancer. pp. S548-S549. [Online].